Latest News and Press Releases

ZUG, Switzerland, 16 March, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical...

ZUG, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address...

ZUG, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the purchase of ordinary shares by a member of the Company’s Board of Directors. Attachments ...

ZUG, Switzerland, March 13, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to trades entered into by a member of the executive committee of the Company pursuant to a 10b5-1 trading plan,...

ZUG, Switzerland, March 11, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to annual equity incentive awards granted to members of the executive committee of the Company. ...

ZUG, Switzerland, March 06, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company. Attachments ...

ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...

ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Following the Company‘s press release published on March 3, the audited consolidated financial statements for the financial year 2025 and the...

ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...

ZUG, Switzerland, March 04, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment ...